## Palynziq (pegvaliase-pqpz) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID NUM	//BER:			
<del>_</del>	BER, YOU WILL NEED TO SUBMIT A PHI DISCLO	HT (LB/KG): ALLERGI		
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):				
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL I	DISPENSING INFORMATION			
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
■ NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:		
DURATION OF THERAPY (SPE	CIFIC DATES):			

Continued on next page.



## Palynziq (pegvaliase-pqpz) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
□ Phenylketonuria □ Other diagnosis:	ICD-10:	
<b>3. REQUIRED CLINICAL INFORMATION</b> PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A
Will patient continue to limit their die	ncentration greater than 600micromol/ et of phenylalanine containing foods? ropterin) while on Palynziq (pegvaliase-	⊐Yes □ No
Renewal Request: Is patient continuing to demonstrate a	a positive clincial response?   Yes   No	Please submit documentation.
Is patient receiving treatment with Ku	ıvan(sapropterin) while being treated w	ith Palynziq? □ Yes □ No
Are there any other comments, diagnophysician feels is important to this rev	oses, symptoms, medications tried or fa view?	iled, and/or any other information the
Please note: Not all drugs/diagnosis ar information is received.	e covered on all plans. This request may	be denied unless all required
the Health Plan, insurer, Medical Grou	n provided is true and accurate to the be p or its designees may perform a routine curacy of the information reported on th	audit and request the medical
Prescriber Signature or Electronic I.D.	Verification:	Date:
you are not the intended recipient, you are her	ompanying this transmission contain confidential eby notified that any disclosure, copying, distribution in error, please not have received this information in error, please not have received this information in error, please not have received this information in error.	tion, or action taken in reliance on the contents

**FAX THIS FORM TO:** 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



and arrange for the return or destruction of these documents.